Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.